Skip to content
Logo@2x
  • About Us
  • Pipeline
  • Publications
  • Investor Relations
  • Contact Us
×
  • About Us
  • Pipeline
  • Publications
  • Investor Relations
  • Contact Us

ASLAN-Pharmaceuticals-Announces-Positive-Interim-Data-From-the-Multiple-Ascending-Dose-Study-of-ASLAN004-in-Atopic-Dermatitis

7 March, 2024 | Comments Off on ASLAN-Pharmaceuticals-Announces-Positive-Interim-Data-From-the-Multiple-Ascending-Dose-Study-of-ASLAN004-in-Atopic-Dermatitis

Recent Posts

  • Eblasakimab Significantly Alleviates IL-4 and IL-13-Induced Bronchial Airway Constriction in COPD-Derived Lung Slices
  • Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
  • Neuromodulation beyond itch is blocked by targeting IL-13Rα1 with eblasakimab
  • Combining Neuroscience And Immunology: Exploring The Neuro-immune Circuitry Behind Itch And Inflammation By Targeting IL-13Rα1With Eblasakimab
  • Exploring the potential of farudodstat, a DHODH inhibitor, as an alopecia areata therapeutic in a novel ex vivo model of human hair follicle immune privilege collapse

Archives

  • May 2024
  • February 2024
  • November 2023
  • October 2023
  • August 2023
  • June 2023
  • May 2023
  • April 2023
  • June 2021
  • February 2021

Categories

  • Clinical publications
  • Eblasakimab
  • Farudodstat
  • Translational work
White Logo

We are a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients

Company

  • Pipeline
  • Eblasakimab
  • Farudodstat
  • Publications
  • About Us
  • Investor Relations
  • Contact Us

Contact Us

US Office

400 Concar Drive
San Mateo, CA 94402
USA

Singapore Office

3 Temasek Avenue,
Level 18,
Singapore 039190

+65 6817 9598

contact@aslanpharma.com

Social Media

© Copyright ASLAN Pharmaceuticals 2025. All Rights Reserved | Website by Singapore Website Designer

Privacy Policy       Terms of Use

Scroll To Top